AU2023208408A1 - Complexes for cancer treatment and imaging - Google Patents

Complexes for cancer treatment and imaging Download PDF

Info

Publication number
AU2023208408A1
AU2023208408A1 AU2023208408A AU2023208408A AU2023208408A1 AU 2023208408 A1 AU2023208408 A1 AU 2023208408A1 AU 2023208408 A AU2023208408 A AU 2023208408A AU 2023208408 A AU2023208408 A AU 2023208408A AU 2023208408 A1 AU2023208408 A1 AU 2023208408A1
Authority
AU
Australia
Prior art keywords
radionuclide
present
complex according
pharmaceutical composition
complex
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2023208408A
Other languages
English (en)
Inventor
Roy H. Larsen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sciencons AS
Original Assignee
Sciencons AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sciencons AS filed Critical Sciencons AS
Publication of AU2023208408A1 publication Critical patent/AU2023208408A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0497—Organic compounds conjugates with a carrier being an organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0474—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group
    • A61K51/0482—Organic compounds complexes or complex-forming compounds, i.e. wherein a radioactive metal (e.g. 111In3+) is complexed or chelated by, e.g. a N2S2, N3S, NS3, N4 chelating group chelates from cyclic ligands, e.g. DOTA
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0402—Organic compounds carboxylic acid carriers, fatty acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nuclear Medicine (AREA)
AU2023208408A 2022-01-21 2023-01-20 Complexes for cancer treatment and imaging Pending AU2023208408A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP22152725.2 2022-01-21
EP22152725 2022-01-21
PCT/EP2023/051355 WO2023139203A1 (en) 2022-01-21 2023-01-20 Complexes for cancer treatment and imaging

Publications (1)

Publication Number Publication Date
AU2023208408A1 true AU2023208408A1 (en) 2024-08-01

Family

ID=79927204

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2023208408A Pending AU2023208408A1 (en) 2022-01-21 2023-01-20 Complexes for cancer treatment and imaging

Country Status (6)

Country Link
US (1) US20250099631A1 (cg-RX-API-DMAC7.html)
EP (1) EP4466032A1 (cg-RX-API-DMAC7.html)
JP (1) JP2025503096A (cg-RX-API-DMAC7.html)
CN (1) CN118891066A (cg-RX-API-DMAC7.html)
AU (1) AU2023208408A1 (cg-RX-API-DMAC7.html)
WO (1) WO2023139203A1 (cg-RX-API-DMAC7.html)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3498308T3 (da) 2017-12-13 2025-01-02 Sciencons AS Kompleks, der omfatter en psma-målrettet forbindelse bundet til et bly- eller thorium-radionuklid

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3498308T3 (da) * 2017-12-13 2025-01-02 Sciencons AS Kompleks, der omfatter en psma-målrettet forbindelse bundet til et bly- eller thorium-radionuklid
CN121534209A (zh) * 2018-09-28 2026-02-17 海德堡大学 前列腺特异性膜抗原(psma)的标记抑制剂,其作为显像剂和药剂用于治疗表达psma的癌症的用途

Also Published As

Publication number Publication date
JP2025503096A (ja) 2025-01-30
US20250099631A1 (en) 2025-03-27
CN118891066A (zh) 2024-11-01
WO2023139203A1 (en) 2023-07-27
EP4466032A1 (en) 2024-11-27

Similar Documents

Publication Publication Date Title
Long et al. Clinical application of 18F-AlF-NOTA-octreotide PET/CT in combination with 18F-FDG PET/CT for imaging neuroendocrine neoplasms
Cook et al. Technetium-99m-labeled HL91 to identify tumor hypoxia: correlation with fluorine-18-FDG
Kvols et al. Evaluation of a radiolabeled somatostatin analog (I-123 octreotide) in the detection and localization of carcinoid and islet cell tumors.
Sainz-Esteban et al. Comparison of sequential planar 177Lu-DOTA-TATE dosimetry scans with 68Ga-DOTA-TATE PET/CT images in patients with metastasized neuroendocrine tumours undergoing peptide receptor radionuclide therapy
Fröberg et al. Comparison of three radiolabelled peptide analogues for CCK-2 receptor scintigraphy in medullary thyroid carcinoma
UA127532C2 (uk) Комплекс, який містить сполуку, що націлюється на psma, зв'язану з радіонуклідом свинцю або торію
Ahmed et al. Diagnostic modalities and radiopharmaceuticals with particular importance of technetium-99m (99mTc)
Zhu et al. Biodistribution and radiation dosimetry of the Enterobacteriaceae-specific imaging probe [18F] fluorodeoxysorbitol determined by PET/CT in healthy human volunteers
Ortiz-Arzate et al. Kit preparation and biokinetics in women of 99mTc-EDDA/HYNIC-E-[c (RGDfK)] 2 for breast cancer imaging
Montilla-Soler et al. Skeletal scintigraphy
Ilem-Ozdemir et al. Nuclear medicine and radiopharmaceuticals for molecular diagnosis
Leichner et al. Patient-specific dosimetry of indium-111-and yttrium-90-labeled monoclonal antibody CC49
Knapp et al. Introduction: radiopharmaceuticals play an important role in both diagnostic and therapeutic nuclear medicine
WO2023139203A1 (en) Complexes for cancer treatment and imaging
US10363324B2 (en) Pharmaceutical composition
Orsini et al. Single-Photon Emitting Radiopharmaceuticals for Diagnostic Applications
Shahzad et al. A new method for synthesis of 99mTc-enorfloxacin: An infection imaging agent
Gholipour et al. Chelator-free radiolabeling of dextran with 68Ga for PET studies
Das et al. Preparation of therapeutic dose of 177Lu-DOTA-TATE using a novel single vial freeze-dried kit: A comparison with ‘in-situ’preparation at hospital radiopharmacy
Cullen et al. Tutorial 14: introduction to nuclear medicine
Workman Jr et al. Fundamentals of PET and PET/CT imaging
Saleh Technetium-99m radiopharmaceuticals
JP4863345B2 (ja) 心筋用放射性画像診断剤又は放射性治療薬
Rizvi et al. In-house production of [99mTc][Tc-HYNIC-TATE] cold kit for the diagnosis of neuroendocrine tumors in Pakistan: pre-clinical and clinical evaluation of indigenously manufactured single and dual vial kit formulation
Bruland et al. Targeted radionuclide therapy in bone cancer